1.51
0.12 (8.24%)
| Penutupan Terdahulu | 1.40 |
| Buka | 1.39 |
| Jumlah Dagangan | 1,524,300 |
| Purata Dagangan (3B) | 3,517,653 |
| Modal Pasaran | 126,406,472 |
| Harga / Jualan (P/S) | 3.48 |
| Harga / Buku (P/B) | 2.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -758.05% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 310.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.88% |
| Nisbah Semasa (MRQ) | 3.08 |
| Aliran Tunai Operasi (OCF TTM) | -208.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -103.52 M |
| Pulangan Atas Aset (ROA TTM) | -36.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -140.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Editas Medicine, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.13 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.35% |
| % Dimiliki oleh Institusi | 54.01% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.00 (Baird, 164.90%) | Beli |
| Median | 3.50 (131.79%) | |
| Rendah | 3.00 (HC Wainwright & Co., 98.68%) | Beli |
| Purata | 3.50 (131.79%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.54 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 13 May 2025 | 4.00 (164.90%) | Beli | 1.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 3.00 (98.68%) | Beli | 1.58 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |